Building on the topics covered in our March 2019 report, this latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences value chain.

With the Iberian nation enjoying an economic rebound, pharmaceutical multinationals are once again seeing Spain as a favourable investment destination, taking into account the country’s Swiss or German quality levels at southern European prices. Indeed, recent years have seen big-ticket infrastructural investments in Spanish manufacturing plants from the likes of Pfizer, Takeda and Bayer.

This trend is also prevalent in the medical devices sphere, with Becton Dickinson and B Braun, to name but two, looking once more to Spain.

Medtech firms are also at the forefront of another key trend tackled in this report: Spain’s move towards a value-based healthcare model and how public and private actors are interacting to create innovative and digital solutions.

Other topics touched on in this comprehensive and wide-ranging report include how the region of Catalonia is forging ahead in healthcare innovation, why Spain is increasingly a happy hunting ground for resourceful generics firms, and how players in niches as diverse as dermo-cosmetics and bugtech are achieving Spanish success.